In signing the communiqué, Johnson & Johnson and 15 other life science companies are committing to prioritize the safety, science and accessibility of the potential vaccines, therapeutic medicines or diagnostic tools they are developing to help fight the pandemic.
When you're the CFO of a company, you have a holistic view of how a pandemic can touch every aspect of a business, especially when it's a healthcare company. So we posed inquiring mind questions to Joe Wolk about what the past eight months have been like for him at the financial helm of the company—via a Zoom interview.
Johnson & Johnson (NYSE: JNJ) (the Company) recently announced the launch of its large-scale, pivotal, multi-country Phase 3 trial (ENSEMBLE) for its COVID-19 vaccine candidate, JNJ-78436735, being developed by its Janssen Pharmaceutical Companies.
We’re pleased to announce that based on interim results from our ongoing studies, the Janssen Pharmaceutical Companies of Johnson & Johnson are launching ENSEMBLE, a large-scale, multi-country Phase 3 trial of a single dose of our vaccine candidate.
As schools reopen—and sometimes close again—what have we learned about the risks of in-person learning? Lisa Ling speaks to school nurse Robin Cogan and pediatrician Dr. Sam Maldonado to find answers and debunk myths around kids and COVID-19.
"We were pleased to share new research at this year's virtual Psych Congress, underscoring Alkermes' commitment to addressing the challenges faced by those living with serious mental illness," said Amy O'Sullivan, Vice President, Health Economics and Outcomes Research at Alkermes.
Cascale shares updates from its Board of Directors who serve as the principal governing body and are responsible for setting the strategic direction...
The SCS Kingfisher certification mark is showing up on an increasing number of products around the world. It differentiates companies that are making...
As the leading sports and live music company in the world, we recognize our responsibility to provide industry leadership and to conduct our business...
